Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of L-Kynurenine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | KYNU | Q16719 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 3/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Kynurenine SCHEMBL3349840 | 1.00 | KDM4E (0.57) | KDM4EHIF1ATDP1KYNUGAA | |
| L-Kynurenine SCHEMBL29415716 | 0.94 | KDM4E (0.64) | KDM4EHIF1ATDP1KYNUGAA | |
| L-Kynurenine SCHEMBL288989 | 0.94 | KDM4E (0.64) | KDM4EHIF1ATDP1KYNUGAA | |
| L-Kynurenine SCHEMBL29396313 | 0.94 | KDM4E (0.64) | KDM4EHIF1ATDP1KYNUGAA | |
| Kynurenine SCHEMBL288988 | 0.94 | KDM4E (0.64) | KDM4EHIF1ATDP1KYNUGAA | |
| L-Kynurenine SCHEMBL20875 | 0.94 | KDM4E (0.64) | KDM4EHIF1ATDP1KYNUGAA | |
| L-Kynurenine SCHEMBL13969610 | 0.94 | KDM4E (0.64) | KDM4EHIF1ATDP1KYNUGAA | |
| Kynurenine SCHEMBL20874 | 0.94 | KDM4E (0.64) | KDM4EHIF1ATDP1KYNUGAA | |
| Kynurenine SCHEMBL2181581 | 0.94 | KDM4E (0.64) | KDM4EHIF1ATDP1KYNUGAA | |
| Kynurenine SCHEMBL29349989 | 0.94 | KDM4E (0.64) | KDM4EHIF1ATDP1KYNUGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263505-A1 | ANTIBODY AGAINST KYNURENINE | SALION GMBH (DE) | 2025-08-21 | — | — | US | disclosed |
| EP-3555615-B9 | MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF KIDNEY FUNCTION METABOLITES | METABOLON INC (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3555615-B1 | MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF KIDNEY FUNCTION METABOLITES | METABOLON INC (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-117224519-A | Application of L-kynurenine as immunomodulator in organ transplantation | 广西大学 | 2023-12-15 | — | — | CN | disclosed |
| US-20230341417-A1 | KYNURENINE: USEFUL BIOMARKER IN ACUTE COVID-19 AND LONG COVID | SALION GMBH (DE) | 2023-10-26 | — | — | US | disclosed |
| CN-116908429-A | Kynurenine: useful biomarkers for acute covd-19 and long term covd | 萨利昂有限责任公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-110088615-B | Mass spectrometry assay for detection and quantification of renal function metabolites | 梅塔博隆股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11619636-B2 | Mass spectrometry assay method for detection and quantitation of kidney function metabolites | METABOLON, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20200217841-A1 | IN VITRO METHOD FOR THE DETERMINATION OF NEURODEGENERATIVE DISEASES | SALION GMBH (DE) | 2020-07-09 | — | — | US | disclosed |
| EP-3635409-A1 | IN VITRO METHOD FOR THE DETERMINATION OF NEURODEGENERATIVE DISEASES | SALION GmbH (DE) | 2020-04-15 | — | — | EP | disclosed |
| US-20190086396-A1 | IN VITRO METHOD FOR THE DETERMINATION OF NEURODEGENERATIVE DISEASES | SALION GMBH (DE) | 2019-03-21 | — | — | US | disclosed |
| WO-2018224696-A1 | IN VITRO METHOD FOR THE DETERMINATION OF NEURODEGENERATIVE DISEASES | SALION GMBH (DE) | 2018-12-13 | — | — | WO | disclosed |
| WO-2010041288-A1 | USE OF L-KYNURENINE AND DERIVATIVES THEREOF FOR THE PREVENTION AND TREATMENT OF DIABETES MELLITUS TYPE 1 | UNIVERSITA' DEGLI STUDI DI PERUGIA (IT) | 2010-04-15 | — | — | WO | disclosed |
| US-6265442-B1 | ADMINISTERING A METABOLIC PRECURSOR; HUNTINGTON DISEASE | THE GENERAL HOSPITAL CORPORATION | 2001-07-24 | — | — | US | disclosed |
| EP-1038516-A1 | Cosmetic composition comprising kynurenine | Uchikuga, Saburoh (JP) | 2000-09-27 | — | — | EP | disclosed |